Progesterone Antagonist and Selective Progesterone Modulator in the Treatment of Excessive Uterine Bleeding

a progesterone modulator and progesterone antagonist technology, applied in blood disorder, extracellular fluid disorder, endocrine system disorder, etc., can solve the problems of difficult management of conditions and significant anemia, and achieve the effect of treating and/or preventing excessive uterine bleeding
US20140100208A1Inactive Publication Date: 2014-04-10PREGLEM
5 Cites 0 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
PREGLEM
Publication Date
2014-04-10
Estimated Expiration
Not applicable · inactive patent
Patent Text Reader

Abstract

Progesterone antagonists and SPRM are useful to prepare a medication for the treatment or the prophylaxis of excessive uterine bleeding in women with spontaneous or iatrogenic coagulation disorders such as thrombopenia, coagulation factor deficiency or anti-coagulant therapy. Treatment will last from 1 day to 180 days.
Need to check novelty before this filing date? Find Prior Art

Description

FIELD OF THE INVENTION

[0001] Progesterone antagonists and SPRM are useful to prepare a medication for the treatment or the prophylaxis of excessive uterine bleeding in women with spontaneous or iatrogenic coagulation disorders such as thrombopenia, coagulation factor deficiency or anti-coagulant therapy. Treatment will last from 1 day to 180 days.BACKGROUND OF THE INVENTION

[0002] Uterine bleeding when abnormal can lead to significant anemia and can even be life-threatening. Anatomical causes such as fibroid, polyps, endometrium carcinoma or endometrium hyperplasia resulting from prolonged un-opposed oestrogens deserve specific treatments which are progestins, or surgery like curettage, endoscopic resection or hysterectomy.

[0003] Dysfunctional uterine bleeding disorders (dysfunctional or abnormal uterine bleeding, metrorrhagia and menorrhagia, hypermenorrhea) are forms of pathological bleeding that are not attributable to organic changes in the uterus (such as, e.g., endometrial carcino...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More